Join Tempus’ Exclusive Pan-Cancer Solid Tumor Screen
Due to demand, enrollment has been extended until August 31, 2024, to accommodate a limited number of additional participants. Complete the form to secure your spot.
Join one of the largest pan-indication screening panels on the market and accelerate your drug development.
Access Tempus’ highly characterized tumor organoids (TOs) to help evaluate the efficacy of your pre-clinical drug candidates, including small molecules, mAbs, and ADCs. Our comprehensive screen covers 60 TOs across 10 indications, facilitating robust multimodal insights to generate and test hypotheses for drug dev.
Email us to learn more about this program.